CompoAtlas

LIVOBLISS (Katuki, Cicoria, Aloe) (Paziņots 2013.)

Testo originale in lettone.

Integratore alimentare registrato in Lettonia

Istantanea del registro del 2 maggio 2025. Non consente di accertare la situazione attuale del prodotto.

Numero pubblicato dal PVD
0000159/2013
Tipo
Integratore alimentare
Stato pubblicato
Stato non fornito in questa esportazione; la data di validità è indicata separatamente
Titolare
TRADO EUROPA, SIA
Fabbricante
Bliss Ayurveda Pvt. Ltd.
Origine
Latvija
Istantanea del registro
2 maggio 2025
Assunzione giornaliera consigliata (testo lettone)
1 tablete 2 reizes dienā
Contenuto pubblicato
tablete pa 1 g
Confezionamento pubblicato
60 tabletes

Questa registrazione non costituisce un’autorizzazione alla vendita in Francia o nell’Unione europea. Non dimostra la sicurezza o l’efficacia del prodotto.

La categoria del registro estero non determina la categoria normativa del prodotto in Francia.

Composizione pubblicata

Nome pubblicatoTesto e quantità pubblicatiIngrediente riconosciutoRuolo o contesto
Dzelzsminerals ; Dzelzs ; 8 ; mgFerVitamina o minerale
Katuka saknes pulverisplants ; Katuka saknes pulveris ; Picrorhiza kurroa Royle. ; 250 ; mgpicrorhiza kurroaPianta
Parastā cigoriņa sēklu pulverisplants ; Parastā cigoriņa sēklu pulveris ; Cichorium intybus L. ; 200 ; mgcichorium intybusPianta
Čebulu terminālijas augļapvalka pulverisplants ; Čebulu terminālijas augļapvalka pulveris ; Terminalia chebula Retz. ; 200 ; mgterminalia chebulaPianta
Andrograpes sausais ekstraktsplants ; Andrograpes sausais ekstrakts ; Andrographis paniculata Nees. ; 200 ; mgandrographis paniculataPianta
Indijas bārbeles augļu sausais ekstraktsplants ; Indijas bārbeles augļu sausais ekstrakts ; Berberis aristata DC. ; 200 ; mgberberis aristataPianta
Alvejas lapas sulas sausais ekstraktsplants ; Alvejas lapas sulas sausais ekstrakts ; Aloe vera L. ; 140 ; mgaloe veraPianta
Smaržīgās selerijas augļu pulverisplants ; Smaržīgās selerijas augļu pulveris ; Apium graveolens L. ; 100 ; mgapium graveolensPianta
Emblikas augļapvalka pulverisplants ; Emblikas augļapvalka pulveris ; Phyllanthus emblica L. ; 100 ; mgphyllanthus emblicaPianta
Garā pipara augļu pulverisplants ; Garā pipara augļu pulveris ; Piper longum L. ; 50 ; mgpiper longumPianta
Melnā pipara augļu pulverisplants ; Melnā pipara augļu pulveris ; Piper nigrum L. ; 50 ; mgpiper nigrumPianta
Balerikas terminālijas augļapvalka pulverisplants ; Balerikas terminālijas augļapvalka pulveris ; Terminalia belerica Roxb. ; 50 ; mgNon riconosciutoRuolo non identificato
Svētijas pulverisplants ; Svētijas pulveris ; Swertia chirata (Wall.)C.B.Clarke ; 240 ; mgswertia chirataPianta
Ingvera sakneņu pulverisplants ; Ingvera sakneņu pulveris ; Zingiber officinale Roscoe. ; 100 ; mgzingiber officinalePianta
Mikrokristāliskā celuloze (E 460)otherIngredients ; Mikrokristāliskā celuloze (E 460)Iscritto come additivo E 460(i) (elenco dell’Unione)Ruolo non identificato
Akācijas sveķi (E 414)otherIngredients ; Akācijas sveķi (E 414)Iscritto come additivo E 414 (elenco dell’Unione)Ruolo non identificato
Talks (E 553b)otherIngredients ; Talks (E 553b)Iscritto come additivo E 553b (elenco dell’Unione)Ruolo non identificato
Magnija stearāts (E 470b)otherIngredients ; Magnija stearāts (E 470b)Iscritto come additivo E 470b (elenco dell’Unione)Ruolo non identificato

Le quantità sono riprodotte come pubblicate. L’esportazione non ne precisa la base: l’assunzione giornaliera consigliata non consente di calcolare una dose al giorno. Non viene stimata alcuna dose giornaliera. I nomi lettoni sono conservati senza traduzione.

Paesi dei produttori

Indija

Testo originale in lettone.

Riferimenti francesi ed europei per gli ingredienti riconosciuti

Gli ingredienti non riconosciuti non vengono valutati. L’assenza di segnalazioni non dimostra la conformità del prodotto.

Fonte ufficiale

Consultare il registro ufficiale

Esportazione ufficiale PVD

Copia di Internet Archive del 3 maggio 2025

PVD, registro degli integratori alimentari, CC0 1.0. Le quantità e la data di ogni istantanea sono conservate come pubblicate.

CC0 1.0

Avvertenze ufficiali (Health Canada)

Health Canada pubblica avvertenze su questi ingredienti:

  • Katuka saknes pulveris
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    KUTKI - PICRORHIZA KURROOA

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: Bitter tonic; Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Controindicazioni

    Condizione di applicazione: All products.

    Do not use if you are pregnant or breastfeeding (Brinker 2010).

    Fonti citate da Health Canada (1)
    • Brinker F. Herbal Contraindications and Drug Interactions: Plus Herbal Adjuncts with Medicines, expanded 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    Fonti citate da Health Canada (2)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard. Ottawa (ON): Drugs and Health Products; Health Canada. [Accessed 2024 January 6]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
    • SC 2009: Santé Canada. Laxatifs : Général. Norme d'Étiquetage des Laxatifs. Ottawa (ON): Médicaments et produits de santé, 2009. [Consulté le 6 janvier 2024]. Disponible à: https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/medicaments/demandes-presentations/lignes-directrices/medicaments-vente-libre-normes-etiquetages-produits-pharmaceutiques/laxatifs-normes-etiquetages-medicaments-vente-libre.html

    Reazioni avverse note

    Condizione di applicazione: Bitter tonic; Liver protectant.

    When using this product you may experience a laxative effect (Sudarshan 2005; API 2001; Kapoor 2001).

    Fonti citate da Health Canada (3)
    • API 2001: The Ayurvedic Pharmacopoeia of India. Part I, Volume II, 1st edition. Delhi (IN): The Controller of Publications; 1991. [Accessed 2018 August 14]. Available from: http://www.ayurveda.hu/api/API-Vol-2.pdf
    • Kapoor LD. Handbook of Ayurvedic Medicinal Plants. Baton Roca (FL): CRC Press LLC; 2001.
    • Sudarshan SR. Encyclopaedia of Indian Medicine, Materia Medica-Herbal Drugs.Volume 4.Banglore (IN): Popular Prakashan; 2005.

    Monografia di Health Canada del 26 luglio 2024

  • Alvejas lapas sulas sausais ekstrakts
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    ALOE VERA LEAF GEL - Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Brinker 2010; Mills and Bone 2005; Bartram 1998).

    Fonti citate da Health Canada (3)
    • Bartram T. Bartram's Encyclopedia of Herbal Medicine, 1st edition. London (GB): Robinson Publishing Ltd; 1998.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Si applica ai prodotti: providing 2.4 g or more fresh leaf gel, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Huseini et al. 2012; Pizzorno and Murray 2006).

    Fonti citate da Health Canada (2)
    • Huseini HF, Kianbakht S, Hajiaghaee R, Dabaghian FH. Anti-hyperglycemic and anti-hypercholesterolemic effects of Aloe vera leaf gel in hyperlipidemic type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Planta Medica 2012;78(4):311-316. PubMed Studio randomizzato
    • Pizzorno J E, Murray M T. Text Book of Natural Medicine, 3rd edition. St. Louis (MO): Elsevier Churchill Livingstone; 2006.

    Condizione di applicazione: Demulcent.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 28 marzo 2025

    ALOE - ALOE VERA/ALOE FEROX - Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a kidney disorder or a lazy bowel (EMA 2016; Gardner and McGuffin 2013; Brinker 2010).

    Fonti citate da Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf
    • Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking heart medications, corticosteroids, diuretics, or other health products that may contribute to electrolyte imbalance (EMA 2016; Gardner and McGuffin 2013; Brinker 2010).

    Fonti citate da Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf
    • Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.

    Controindicazioni

    Do not use if you are pregnant or breastfeeding (Gardner and McGuffin 2013; Brinker 2010).

    Fonti citate da Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.

    Do not use if you have inflammatory bowel disease, fever or any undiagnosed gastrointestinal trouble (EMA 2016; Gardner and McGuffin 2013; Brinker 2010).

    Fonti citate da Health Canada (3)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf
    • Gardner Z, McGuffin M. editors. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press; 2013.

    Reazioni avverse note

    Stop use if hypersensitivity/allergy or diarrhea occurs (EMA 2016; Brinker 2010).

    Fonti citate da Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2016. European Medicines Agency. Community Herbal Monograph on Aloe Barbadensis Miller and on Aloe (Various Species, Mainly Aloe Ferox Miller And Its Hybrids). London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 Novembre 2016. [Accessed 2025 March 14]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-aloe-barbadensis-mill-and-aloe-various-species-mainly-aloe-ferox-mill-and-its-hybrids-folii-succus-siccatus_en.pdf

    Monografia di Health Canada del 28 marzo 2025

    ALOE - ALOE VERA Topical

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Reazioni avverse note

    Stop use if hypersensitivity/allergy occurs (Gardner and McGuffin 2013; Brinker 2010).

    Fonti citate da Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M. éditeurs. American Herbal Products Association's Botanical Safety Handbook, 2e édition. Boca Raton (FL): CRC Press; 2013.

    Monografia di Health Canada del 29 agosto 2025

  • Emblikas augļapvalka pulveris
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    Amla - Phyllanthus Emblica

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Condizione di applicazione: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (HC 2009).

    Fonti citate da Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Si applica ai prodotti: providing more than 3 grams of amla, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (HC 2009).

    Fonti citate da Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Condizione di applicazione: Amlapitta, Digestive tonic.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condizione di applicazione: Laxative.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen or if laxative effect does not occur within 7 days (HC 2009; Pray 2006; CPhA 2002).

    Fonti citate da Health Canada (3)
    • CPhA 2002: Repchinsky C, editor-in-chief. Patient Self-Care: Helping Patients Make Therapeutic Choices. 1st edition. Ottawa (ON): Canadian Pharmacists Association; 2002.
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html
    • Pray WS. Non-Prescription Product Therapeutics. 2nd edition. New York (NY): Lippincott Williams & Wilkins; 2006.

    Controindicazioni

    Condizione di applicazione: Laxative.

    Do not use if you have fever or any undiagnosed gastrointestinal trouble (HC 2009).

    Fonti citate da Health Canada (1)
    • HC 2009: Laxatives: General - Laxatives - Labelling Standard [Internet]. Ottawa (ON): Drugs and Health Products; Health Canada; 2009. [Accessed 2023 December 31]. Available from: https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/nonprescription-drugs-labelling-standards/laxatives-labelling-standards-non-prescription-drugs.html

    Reazioni avverse note

    Condizione di applicazione: Amlapitta, Antioxidant, Digestive tonic, Rasayana or Eye tonic.

    When using this product you may experience a laxative effect.

    Monografia di Health Canada del 28 marzo 2025

  • Ingvera sakneņu pulveris
    Leggere l'avvertenza, quando si applica e gli studi citati

    Testo originale ufficiale in inglese.

    GINGER - ZINGIBER OFFICINALE

    Via di somministrazione: Oral

    Precauzioni e avvertenze

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Monografia di Health Canada del 19 dicembre 2025

Riguardano l'ingrediente, non questo prodotto né la sua dose. Non sostituiscono il parere medico.

La data della prova di questo elenco di ingredienti è sconosciuta.

Il prodotto è cambiato? Fotografi la confezione.

Un'informazione inesatta o più recente su questo prodotto, che lei sia lettore o marca? Scriva a contact@compoatlas.com: ogni correzione è pubblicata nel registro delle correzioni.

Invio per analizzare, Maiusc+Invio per una nuova riga